Recently, the fifth New Economy Enterprise High-Quality Development Conference, organized by the China Enterprise Evaluation Association, was held in Shanghai. The theme of the conference was "Artificial Intelligence Driving New Economic Development," which facilitated an in-depth exploration of new pathways for economic growth.

During the conference, the "2024 Top 500 New Economy Enterprises" list was announced, with Eyebright Medical being recognized for the fourth consecutive year.

The "new economy" is characterized by the emergence of new industries, business formats, and models. It is distinguished by rapid growth, a strong emphasis on the real economy, high technological content, fulfillment of practical demands, job creation, and sustainability.

As a representative of new economy enterprises in the ophthalmic medical device sector, Eyebright Medical consistently prioritizes research and innovation. The company has launched several pioneering ophthalmic medical products, both nationally and internationally.

At the beginning of 2025, Eyebright Medical's refractive surgery product, the Loong Crystal™ PR phakic intraocular lens, received NMPA approval, expected to challenge the long-standing dominance of the ICL products in the Chinese and global markets. The first batch of patients in several cities nationwide has already undergone implantation, resulting in significant improvements in post-operative vision and positive outcomes.

Looking ahead, Eyebright Medical will continue to advance ophthalmic medical technology and product upgrades, align with emerging economic trends, explore innovative models, and lead high-quality development in the ophthalmic medical device industry.

※Unless otherwise stated or indicated, any reproduction, redistribution, transmission, download, unauthorized use without prior written approval of Eyebright Medical, is expressly and strictly prohibited.